What Genovac does

Genovac Antibody Discovery is a privately held contract research and manufacturing organization (CRO/CMO) that provides integrated antibody discovery, production, and characterization services to biopharmaceutical, biotechnology, diagnostic, and academic customers across North America, Europe, Australia, and Asia. The company was originally founded in 1999 by three University of Freiburg professors in Germany and operated for a period as part of Aldevron before a 2020 management-led buyout relaunched it as an independent entity with US headquarters at the North Dakota State University Research & Technology Park in Fargo, ND, and a European scientific and production facility in Freiburg, Germany.

Genovac's core technical stack combines proprietary genetic immunization (which enables antibody generation directly from DNA without purified antigen) with multiple single B cell screening platforms — Berkeley Lights Beacon optofluidic systems (three instruments), the proprietary Genovac Nano bead-based platform, and 10X Genomics ChromiumX — plus advanced hybridoma workflows across diverse host species (mouse, rat, rabbit, llama, alpaca, and human PBMCs). Downstream capabilities include HEK and CHO antibody production, Carterra LSA HT-SPR and Gator Bio BLI characterization, functional assays, antibody sequencing, and a 2024-launched AI-based humanization service (GenovacAI) powered by ENPICOM's AIGX generative deep learning model. Catalog antibodies and an online plasmid DNA store (plasmidusa.com) provide additional transactional revenue.

The business model is primarily fee-for-service project-based contract research, with quote-based pricing, complemented by milestone- and royalty-based licensing income (notably an exclusive worldwide agreement with Pfizer announced in September 2023 for therapeutic antibody candidates). GTM is sales-led with consultative selling, complimentary target analysis, dedicated regional sales contacts for the US/Canada and Europe, conference presence (Festival of Biologics, Antibody Engineering & Therapeutics), and co-marketed webinars with technology partners. The company has completed more than 3,600 antibody discovery projects since 1999 and counts major pharma clients including Pfizer, Eli Lilly, and AbCellera among its enterprise users.

Name

Genovac

Legal name

Genovac Antibody Discovery, LLC

Website

https://genovac.com

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

101–250 employees

Short description

Genovac is a private CRO/CMO offering integrated antibody discovery, production, and characterization services — built on genetic immunization and single B cell platforms — to biopharma, biotech, diagnostic, and academic clients across four continents.

Ownership category

akta.pro rank

Product category

Antibody Discovery Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Antibody discovery services
• Contract research organization
• Single B cell screening
• Therapeutic antibody development
• Hybridoma technology

Headquarters

HQ city

Fargo

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Contract Research Services: Genovac provides fee-for-service antibody discovery, production, and characterization services to biotech and pharmaceutical companies. Projects are scoped individually with quotes and proposals, generating revenue through project-based fees.
2. Catalog Antibodies: Sale of pre-made catalog antibodies for research use. Products include antibodies against various targets (IL-13R, IL17RB, Granzyme K, CEACAM family, etc.) sold at standard quantities (100ug).
3. Plasmid DNA Production: Online store sales of plasmid DNA preps at various scales (Maxi, Mega, Giga, High-Throughput Mini/Midi) and custom orders. Revenue from product sales at different quality levels.
4. Licensing and Royalties: Exclusive licensing agreements with pharmaceutical companies for therapeutic antibody candidates. Receives upfront payments, milestone payments, and royalties on net sales of commercial products.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Genovac is a contract research organization that provides antibody discovery, production, and characterization services to biotech and pharmaceutical companies. The core offering spans a gene-to-antibody workflow using genetic immunization, single B cell screening platforms (Beacon, Genovac Nano, ChromiumX), advanced hybridoma technologies, antibody production in HEK/CHO hosts, AI-powered humanization, and high-throughput binding characterization via Carterra LSA. The company also sells catalog antibodies and operates an online plasmid DNA storefront.

Product overview

Genovac is a contract research and manufacturing organization (CRO/CMO) offering integrated antibody discovery and production services. The core offerings include genetic immunization, advanced hybridoma, and single B cell screening platforms (Beacon, Genovac Nano, ChromiumX) for antibody discovery against challenging targets like GPCRs and ion channels. These core discovery technologies feed into integrated production and characterization services including high-throughput and scale-up antibody production in HEK/CHO cells, binding kinetics and epitope binning using Carterra LSA HT-SPR and Gator Bio BLI instruments, and functional assays. Additional services include AI-powered humanization (GenovacAI), antibody sequencing, recombinant protein production, and plasmid DNA manufacturing. Genovac also offers catalog antibodies and an online plasmid store. The portfolio spans from gene to antibody, providing clients with a comprehensive one-stop-shop solution for biologics development.

Differentiator

Problem solved

Functional benefit

Products and services

• Immunization Strategies Genetic immunization technology enabling development of antibodies against any protein target directly from DNA, electronic sequence, or accession number. Includes proprietary screening vectors for identification of positive antisera, single B cells, and hybridomas without purified antigen.
• Single B Cell Platforms Multiple automated single B cell antibody discovery platforms including Bruker's Beacon Optofluidic system, Genovac Nano bead-based screening, and 10X Genomics ChromiumX with NGS for rare antibody discovery.
• Advanced Hybridoma Highly efficient semi-solid and well-based fusion options for rapid delivery of antibodies comparable to yields of manual single B cell platforms, compatible with wild type and transgenic species.
• Multi-Species Host Options Multiple wild type and human-Ig transgenic species including mouse, rat, rabbit, llama, alpaca, and human PBMC for generating superior human therapeutic antibody candidates.
• GenovacAI Humanization AI-based humanization service using generative deep learning algorithms (AIGX model) to humanize antibodies with high success rates. Enables humanization-forward engineering of multiple candidate antibodies post-discovery.
• Antibody Sequencing In-house hybridoma and single B cell antibody sequencing using Sanger and NGS techniques, including sequence analysis through ENPICOM software for phylogenetic analysis and CDR3 identification.
• Antibody Production High-quality antibody production services from small-scale high-throughput parallel production (up to 96 antibodies per batch) through scale-up production (1.4-20L culture volumes) in HEK or CHO hosts.
• Antibody Characterization Binding kinetics and epitope binning services using Carterra LSA HT-SPR platform (up to 384 antibodies for kinetics, 192x192 array for binning) and Gator Bio Gator Plus BLI (up to 24 antibodies).
• Antibody Functional Assays Functional characterization services including binding, cross reactivity, blocking, internalization, neutralization, and cytotoxicity assays using Incucyte, SpectraMax, Attune Flow Cytometers, and iQue platforms.
• Plasmid DNA Production Plasmid DNA production at microgram to gram scale with research grade and enhanced research grade quality levels, including process development and full quality testing suite.
• Recombinant Protein Production Flexible recombinant protein production from small-scale parallel to multi-gram scale in E. coli, HEK-293, and CHO cells with comprehensive purification and analytics.
• Catalog Antibodies Pre-generated catalog antibodies against various human targets including IL-13R, IL17RB, Granzyme K, ICOSL, FASL, CEACAM family, CCR4, LGR4/5, CD34, EphA2, VEGFR2, and others for research use.
• Plasmid Store (plasmidusa.com) Online ordering platform for standard and custom plasmid DNA preps including Maxi, Mega, Giga, and High-Throughput options at various purity and quantity levels.

Quantifiable outcome

• 100x faster antibody characterization with 99% less sample using Carterra LSA
• +3 more outcomes

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered flagship, core and supporting.

• PfizerflagshipStrategic or Co-development Partner · 19 September 2023Exclusive worldwide licensing agreement for therapeutic antibody candidates generated by Genovac in collaboration with a leading research university. Genovac receives upfront payment, development and commercial milestone payments, plus royalties on net sales of commercial products.
• North Dakota State University (NDSU)coreStrategic or Co-development Partner · 13 March 2023Public-private research collaboration focused on discovering high-quality antibodies against RAGE receptor for therapeutic development targeting melanoma and pancreatic cancer. NDSU researchers perform preclinical evaluation while Genovac provides discovery and production capabilities.
• ENPICOMcoreTechnology or Integration · 2 May 2022Genovac uses ENPICOM's IGX Platform for advanced data management and computational analysis in antibody discovery workflows. The partnership also includes joint development of GenovacAI Humanization service powered by ENPICOM's AIGX generative deep learning model.
• CarterracoreTechnology or Integration · 20 April 2022Genovac acquired Carterra's LSA platform, a high-throughput antibody screening and characterization technology. The LSA platform uses high-throughput surface plasmon resonance (HT-SPR) technology and is the standard in 16 of the 20 largest pharmaceutical companies. The platform was used in discovery of COVID-19 therapeutics including bamlanivimab.
• Berkeley LightscoreTechnology or Integration · 5 October 2021Partnership for Beacon Optofluidic System for single-cell screening. Genovac operates three Beacon instruments and became the first CRO to leverage the technology for both antibody discovery and cell line development. The technology enables screening of up to 160,000 B cells per project and has dramatically improved success rates on challenging targets.
• 10X GenomicssupportingTechnology or IntegrationGenovac offers single B cell services using 10X Genomics Chromium X instrument combined with NGS sequencing for high-throughput screening of up to 240,000 cells per day with full-length V(D)J sequences.
• Gator BiosupportingTechnology or IntegrationPartnership for Gator Plus biolayer interferometry (BLI) platform for binding kinetics and epitope binning as a cost-effective option for smaller antibody sets (up to 24 antibodies for kinetics, 12x12 arrays for binning).

Scale indicators5 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• AbCellera Biologics: Public antibody discovery CRO combining single B cell screening, AI/ML, and a technology stack similar to Genovac's Beacon-based workflow. Closest publicly traded peer in business model and target customer base.
• Adimab: Private antibody discovery platform CRO serving pharma and biotech with proprietary yeast-based discovery. Direct competitor for outsourced antibody discovery programs targeting challenging proteins.
• AlivaMab Discovery Services: Transgenic-animal-based antibody discovery CRO offering humanized antibody generation from OmniAb platform animals. Closest direct peer to Genovac's transgenic host species (mouse, rat, rabbit, llama) offering.
• LakePharma (Curia): Antibody discovery and development CRO, now part of Curia, offering hybridoma, B cell cloning, and characterization services that directly overlap Genovac's discovery-to-production pipeline.
• Distributed Bio (Charles River Laboratories): Antibody discovery CRO (now part of Charles River) with SuperHuman and AbGenesis platforms; competes head-to-head with Genovac for therapeutic antibody discovery programs at biotech and pharma clients.
• GenScript ProBio: Biologics CDMO offering antibody discovery, cell line development, and GMP manufacturing. Comparable end-to-end biologics service portfolio with greater scale and global footprint.
• Absolute Antibody: Specialized antibody services company offering antibody sequencing, engineering, and recombinant production. Comparable in catalog and recombinant antibody services to Genovac's catalog and production offerings.

Broad incumbents

• Lonza Biologics: Global CDMO leader in biologics manufacturing with growing discovery services. Larger, established player with integrated discovery-through-GMP offering that competes with Genovac at the high end of the market.
• WuXi Biologics: Largest pure-play biologics CDMO globally with integrated antibody discovery through commercial manufacturing. Sets pricing and scale benchmarks against which specialized discovery CROs like Genovac must compete.
• Catalent Biologics: Major CDMO offering biologics development and manufacturing with GPEx cell line platforms. Notable as the prior employer of Genovac's VP Pete Leland and a comparable end-to-end biologics service provider.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genovac

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genovac